Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Eckert & Ziegler BEBIG: Eckert & Ziegler buys Belgian provider of brachytherapy accessories

Eckert & Ziegler BEBIG
Posted on: 26 Aug 16

Press Release

Regulated information

26 August 2016, 06:00 p.m.

Seneffe, August 26, 2016. Eckert & Ziegler BEBIG SA took over 100 % of the shares in BrachySolutions BVBA effective August 26, 2016. The company, which is based in Leuven, Belgium, is one of the largest independent European distributors of prostate seeds. Its main markets are Benelux and Portugal. Both parties have agreed not to disclose the purchase price. 

Through the takeover, Eckert & Ziegler is acquiring BrachySolutions' customer base in Benelux, the United Kingdom, and Portugal, thereby securing its strong position in Europe as a manufacturer of seeds.

"By acquiring BrachySolutions, we are further honing our strategic focus. Our strategy centers on consolidating the market, cementing our market position in Europe, and creating synergies within our portfolio of solutions," said Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG and member of the Board of Directors.

"Eckert & Ziegler's Berlin-made prostate implants stand for top quality. I believe firmly that our brachytherapy customers will continue to receive the best possible products and excellent service in the future," Luk Herremans, founder and Managing Director of BrachySolutions, added.

Brachytherapy is a medical treatment method that includes placing implants containing radioisotopes directly into tumor tissue. The local radiation provided by the implants leads to the destruction of cancer cells. Permanent brachytherapy is mainly used to treat prostate cancer.  

About Eckert & Ziegler BEBIG

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe, in the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line. The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists. Eckert & Ziegler BEBIG employs more than 120 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.com  



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Eckert & Ziegler BEBIG via GlobeNewswire
HUG#2037561
GlobeNewswire
globenewswire.com

Last updated on: 27/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.